Abstract Body

It is estimated that a third of all mother-to-child transmission (MTCT) of HIV occurs among women with incident infection during pregnancy, making repeat HIV testing during the late antenatal period a crucial time to identify and initiate treatment for women who acquire HIV infection. International recommendations, adopted as part of the Kenya HIV Testing Services guidelines, suggest that pregnant women in generalized epidemic settings be offered retesting three months after an initial negative HIV test early in pregnancy.

Longitudinal analyses were conducted in a sample of 2164 women attending antenatal care (ANC) at a rural district hospital in Migori County, Kenya. Data were abstracted from registers for all women who attended ANC from the years 2011 to 2014.

The majority of women (1954/2164, 90.2%) presented for their first ANC visit early enough (≤ 28 weeks gestation) to later be eligible for retesting, but several missed opportunities were noted including: (a) 310 (15.8%) women never returned to ANC and thus were considered to have an unknown HIV status at delivery; of the 495 women who returned to ANC when eligible, (b) only 132 (36.6%) were retested and (c) 126 (25.5%) failed to be retested even though eligible at two or more visits. On retest, two women tested HIV-positive, suggesting a seroconversion rate of 1.5% from early to late pregnancy. Although most women came early in pregnancy and a quarter had at least 4 ANC visits, 59.7% of all women had unknown HIV status at delivery. For a minority of women (210/2164, 9.8%) who presented later (>28 weeks gestation) for their first ANC visit, retesting is not standard protocol. However, among them 8 (3.8%) tested HIV-positive, possibly constituting a missed opportunity for early antiretroviral therapy (ART) initiation.

Missed opportunities for repeat HIV testing and early ART initiation among pregnant women may contribute to continuing high rates of MTCT in Kenya and similar settings in sub-Saharan Africa, particularly in light of current recommendations that all pregnant women who test HIV-positive be started immediately on ART. Extrapolating the seroconversion rate to all women who missed a retest would suggest that potential cases of MTCT are slipping through the cracks. Contributors to missed opportunities include patient factors, such as not returning to ANC after testing negative for HIV early in pregnancy, and health system factors, such as a failing to retest eligible women.